Platelet Derived Growth Factor
This information was provided by Curative Technologies, Inc.
1-516-689-7000
General Information
Process
Reimbursement
- Refer to an article entitled "The use of topically
applied platelet growth factors in Chronic nonhealing
wounds: A Review" in the April 1989 issue of Wounds:
A Compendium of Clinical Research and Practice. This
article provides more information on some of the subjects
discussed below.
- The various cascade systems are critical in wound repair.
- Platelets and macrophages are seen as the main regulatory
cells in wound repair.
- Platelets contain at least 5 growth factors. These growth
factors aid in the formation of granulation tissue and
re-epithelialization.
- The 5 growth factors mentioned above are:
- Platelet-derived growth factor (PDGF)
- Platelet-derived angiogenesis factor (PDAF).
- Platelet-derived epidermal growth factor (PDEGF)
- Transforming growth factor-beta (TGFB)
- Platelet Factor 4 (PF-4)
(these all have specific roles and functions to aid in wound
repair) (1)
- Growth factors can be obtained from the patient by
drawing their own blood or from other sources such as
yeast, bacteria and other nonhuman mammalian cells. (2)
- The theory behind topical application of growth factors
is that these activated platelets will stimulate the
cascade systems, providing more rapid healing.
- Once a patient is deemed a candidate for this type of
treatment, a specified amount of blood is drawn from that
patient. (between 50 - 200 cc's).
- The platelets are spun down, separated and activated with
thrombin.
- This substance is then packaged into individual vials for
topical application.
- While protocols vary depending on the wound, it is not
uncommon to apply the product on a daily basis.
- One drawing of the patient's blood can typically yield
between 70 and 90 vials, representing almost 3 months of
daily application. The remainder is frozen.
- Check with the patient's insurance company to find out
what costs the policy covers.
- Currently, (as with other pharmaceuticals) Medicare does
not cover the cost of the product.
1.
Knighton, David et. al.,The Use of Topically Applied Platelet
Growth Factors in Chronic Nonhealing Wounds:A Review, Wounds: A
Compendium of Clinical Research and Practice. April 1989
2. Holloway, G. et. al.,
A Randomized, Controlled, Multicenter, Dose Response Trial of
Activated Platelet Supernatent, Topical CT-102 in Chronic,
Nonhealing, Diabetic Wounds, Wounds, A Compendium of Clinical
Research and Practice. Volume 5, Number 4, July/August 1993.
|
